Business ❯ Investing

Pharmaceuticals

Manufacturing Biotechnology Research and Development Roche Eli Lilly AstraZeneca Biopharmaceuticals Biologics Medical Devices Biologics Manufacturing Merck Drug Manufacturing Mining Regeneron Pharmaceuticals Life Sciences Vaccine Development Healthcare Industry Weight-Loss Drugs Active Pharmaceutical Ingredients Global Expansion Ophthalmology Contract Manufacturing Multinational Companies Infrastructure Veterinary Medicine Job Creation Weight Loss Biotech Stocks Concussion Drugs Mexico

Eli Lilly Pours $4.5 Billion Into Indiana Plants, Opens Genetic-Medicine Site

The buildout strengthens U.S. supply for high‑demand obesity drugs plus diabetes treatments.

AbbVie to Build $1.4 Billion Injectable-Medicines Campus in Durham, N.C.

UCB Picks Georgia’s Rowen for $2 Billion Biologics Campus

Novo Nordisk Extends Weight‑Loss Lead as Amgen’s Once‑Monthly MariTide Reaches Phase 3

Novo Nordisk Invests €432 Million to Expand Athlone Plant for Oral GLP-1 Tablets

AbbVie to Invest $380 Million in Two North Chicago API Plants

Johnson & Johnson to Build $1 Billion Cell Therapy Plant in Pennsylvania

Eli Lilly Picks Lehigh Valley for $3.5 Billion Plant to Make Next-Gen Weight-Loss Drugs

AstraZeneca Pledges $15 Billion China Expansion Through 2030

Sanofi, Dren Bio Set Autoimmune Collaboration Worth Up to $1.7 Billion With $100 Million Upfront

Merck Breaks Ground on $3 Billion Virginia Plant in $70 Billion U.S. Expansion

AstraZeneca Breaks Ground on $4.5 Billion Virginia Plant With Expanded Cancer and Obesity Drug Production

Eli Lilly Chooses Houston for $6.5 Billion Plant to Produce APIs for Orforglipron and Other Drugs

J&J Commits $2 Billion to 10-Year Fujifilm Deal for North Carolina Biologics Hub

AbbVie to Build $195 Million API Facility in North Chicago

AstraZeneca Commits $50 Billion to U.S. Manufacturing and Research by 2030